Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.76 |
| ▸ | CTSK | P43235 | 5/20 | 0.76 |
| ▸ | ACE | P12821 | 4/20 | 0.56 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613640 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL4600435 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL29401990 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL17137918 | 0.95 | CTSS (0.77) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL17137921 | 0.95 | CTSS (0.77) | CTSSCTSKACEMMECPA1 | |
| Dipentylamine SCHEMBL9536578 | 0.89 | CTSK (0.63) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL345085 | 0.89 | CTSK (0.65) | CTSSCTSKACEPTPN1CYP3A4 | |
| SCHEMBL7288479 | 0.89 | CTSK (0.65) | CTSSCTSKACEPTPN1CYP3A4 | |
| SCHEMBL8662603 | 0.89 | CTSS (0.62) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL8554176 | 0.89 | CTSS (0.74) | CTSSCTSKACEMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113105524-B | Polypeptide derivative copper complex, preparation method and application thereof, and anticancer drug | 首都医科大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-112691081-B | Paclitaxel micelle based on (S) -2-decanoylamino-3- (1-naphthyl) propionyl-leucyl-valine | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| CN-113260365-A | Novel compound and pharmaceutical composition for enhancing anticancer activity comprising the same | 治愈医药社株式会社 | 2021-08-13 | — | — | CN | disclosed |
| CN-113105524-A | Polypeptide derivative copper complex, preparation method and application thereof, and anticancer drug | 首都医科大学 | 2021-07-13 | — | — | CN | disclosed |
| CN-112691081-A | Paclitaxel micelle based on (S) -2-decanoylamino-3- (1-naphthyl) propionyl-leucyl-valine | 首都医科大学 | 2021-04-23 | — | — | CN | disclosed |
| CN-112279887-A | Amino acid derivative, preparation method and application thereof, anti-tumor micelle and preparation method thereof | 首都医科大学 | 2021-01-29 | — | — | CN | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| WO-2019077507-A1 | PROCESS FOR PREPARATION OF LANREOTIDE ACETATE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2019-04-25 | — | — | WO | disclosed |
| WO-2017178950-A1 | PROCESS FOR PREPARATION OF LANREOTIDE ACETATE | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-10-19 | — | — | WO | disclosed |
| EP-0845002-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1998-06-03 | — | — | EP | disclosed |
| US-5677282-A | ENZYME INHIBITOR; OSTEOARTHRITIS AND RHEUMATIC DISORDERS | PROSCRIPT, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040745-A2 | AMINO ACID AMIDES OF 5-AMINO-1,3,4-THIADIAZONES AND THEIR USE AS INHIBITORS FOR MATRIX METALLOPROTEINASES | PROSCRIPT, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4904660-A | HYPOTENSIVE AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1990-02-27 | — | — | US | disclosed |
| EP-0281316-A2 | Renin inhibitors | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-09-07 | — | — | EP | disclosed |
| EP-0210545-A2 | Phosphorous containing enzyme inhibitors | MERCK & CO. INC. (US) | 1987-02-04 | — | — | EP | disclosed |
| EP-0209897-A2 | Peptide enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | disclosed |
| EP-0209848-A2 | Enzyme inhibitors | MERCK & CO. INC. (US) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | CTSS 332/4885CTSK 1160/4885ACE 4/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | CTSS 332/4885CTSK 1160/4885ACE 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.